UNSPSC 51292919: Dibenzepin hydrochloride

This classification denotes the hydrochloride form of a dibenzazepine and tricyclic antidepressive agent with the molecular formula C18H21N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 510SJZ1Y6L, chemically known as 5,10-dihydro-10-(2-(dimethylamino)ethyl)-5-methyl-11h-dibenzo(b,e)(1,4)diazepin-11-one but more generally known as dibenzepin, which bears US NIH Compound Identifier 9419. European Medicines Agency schedules Dibenzepin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07074MIG.

UNSPSC 51292919 Dibenzepin hydrochloride is a Commodity code that nominally addresses pharmaceutical active ingredients, yet the recent state and local procurement activity posted under this code shows a mismatch with its scope. The single identified recent opportunity, Seminole County, Florida's IFB 60459723LAS, solicits Naloxone and Safe Drug Deactivation Systems—public health commodities unrelated to dibenzepin hydrochloride. This misalignment suggests either a tagging error in the source data or that the code is used inconsistently by the issuing jurisdiction. The opportunity itself reflects county-level demand for overdose-reversal and drug-disposal products in support of community health initiatives.

Seminole County posted the IFB on June 30, 2026, with a response deadline of July 26, 2023 (the date discrepancy appears in the source). The procurement calls for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually, delivered quarterly to the Seminole County Community Health Building in Sanford, Florida. The contract carries a two-year initial term with an optional one-year renewal and requires vendors to meet standard compliance thresholds, including drug-free workplace certification, E-Verify enrollment, and specified insurance coverage. The opportunity identifies potential FEMA funding, which introduces federal environmental and regulatory compliance obligations. No explicit small-business or disadvantaged-enterprise set-asides appear in the posting. The code shows minimal recent activity and marginal relevance to state and local procurement under its nominal pharmaceutical scope; activity under this code warrants verification against actual commodity descriptions before pursuit.